Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data

PURPOSE: Cyclin dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) modulate endocrine resistance and are integral treatment for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Since their appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Razeq, Hikmat, Sharaf, Baha’, AlMasri, Rama, Abdel-Razeq, Rashid, Tamimi, Faris, Khader, Omar, Salama, Osama, Abunasser, Mahmoud, Edaily, Sarah, Abdulelah, Hazem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921668/
https://www.ncbi.nlm.nih.gov/pubmed/35300061
http://dx.doi.org/10.2147/CMAR.S353584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921668/
https://www.ncbi.nlm.nih.gov/pubmed/35300061
http://dx.doi.org/10.2147/CMAR.S353584

Ejemplares similares